Company profile: Selexis
1.1 - Company Overview
Company description
- Provider of proprietary technology and highly specialized expertise for mammalian (suspension-adapted CHO-K1) cell line generation, helping translate scientific innovation into life-saving medicines for patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Selexis
Confluence Life Sciences
HQ: United States
Website
- Description: Provider of rational drug design-based discovery and development of mechanistically novel kinase inhibitors for human and animal health care, targeting key signal transduction enzymes involved in regulating cancer growth and survival and modulating chronic inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Confluence Life Sciences company profile →
Trellis Bioscience
HQ: United States
Website
- Description: Provider of therapeutic antibody therapies for infectious diseases and oncology, developing TRL1068 to disrupt bacterial biofilms and enhance antibiotics in prosthetic joint infections, TRL404 pan-influenza antibody cocktail, TRL3D3 targeting RSV, and TRL345 against cytomegalovirus, enabled by the CellSpot platform to discover high-affinity monoclonal antibodies from human memory B-cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trellis Bioscience company profile →
Inotrem
HQ: France
Website
- Description: Provider of immunotherapies targeting the TREM-1 pathway, including nangibotide, a synthetic peptide and first-in-class TREM-1 inhibitor for acute inflammatory syndromes (septic shock, severe COVID-19); a monoclonal antibody program for chronic inflammatory and fibrotic diseases and immuno-oncology; and a companion diagnostic with Roche Diagnostics measuring soluble TREM-1 in blood to identify septic shock patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inotrem company profile →
Genelux
HQ: United States
Website
- Description: Provider of diagnostic and therapeutic solutions for cancer and inflammatory diseases, featuring oncolytic vaccinia virus programs: Olvi-Vec for ovarian and lung cancers (intraperitoneal or intravenous), V2ACT Immunotherapy combining oncolytic immunotherapy with adoptive cell therapy for pancreatic cancer (systemic), and V-VET1 for canine cancers (intravenous).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genelux company profile →
CEL-SCI
HQ: United States
Website
- Description: Provider of immunotherapy products and technology targeting cancer and infectious diseases, including Multikine, an investigational therapy for advanced primary head and neck cancer intended for use before any other therapy; LEAPS, a platform with candidates for rheumatoid arthritis and other autoimmune and infectious diseases; and a global Phase III trial of Multikine aiming to support potential FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CEL-SCI company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Selexis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Selexis
2.2 - Growth funds investing in similar companies to Selexis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Selexis
4.2 - Public trading comparable groups for Selexis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →